Research that Identifies
Undiscovered Value in the MicroCap Market


Catasys, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC Filings

Report Link: Initial Research Report (Dated 10/17/2017)

Symbol: CATS
Analyst: John Nobile
Taglich Rating: Speculative Buy
Price Target: $8.00
Time Horizon: 12 Months
Rating Established: October 17, 2017
Price When Established: $3.93
Most Recent Report: October 17, 2017
Price When Issued: $3.93

What's New

Catasys Reports Q3 Results

On November 14, 2017, Catasys, Inc. (NASDAQ: CATS) reported results for its third quarter ended September 30, 2017.

For the quarter, the company reported that revenue decreased 11% to $1.2 million. Catasys reported a net loss of $3.1 million or $(0.19) per share versus a net loss of $7.4 million or $(0.81) per share in the comparable quarter in 2016.

Taglich Brothers’ estimates were for third quarter revenue of $2 million and a net loss of $2.7 million or $(0.16) per share.

Company Description

Catasys, headquartered in Los Angeles, California, provides specialized behavioral health management and integrated treatment services to health plans through its proprietary OnTrak™ solution. OnTrak utilizes proprietary analytics in integrating medical and psychosocial treatments with care coaching in a 52-week outpatient program. OnTrak is designed to improve a member’s health while lowering costs to the insurer where behavioral health conditions are causing or exacerbating medical conditions.

Company Reports

Initial Research Report (Dated October 17, 2017)


Please view our current disclosure and disclaimer on our most recent research report.